Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
APLS.US
id: 433, Created by Stan Vick Chase, Scout
Apellis Pharmaceuticals Inc
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
On November 3, 2022, Apellis Pharmaceuticals (APLS) disclosed an unexpected delay in the request for approval of its eye-disease treatment.
Apellis decided to include two-year data from studies called Derby and Oaks in its request for approval of its drug, pegcetacoplan. It will likely delay the FDA's review by three months. The Regulator was previously scheduled to make a decision on the Apellis drug in November 2022. Going back, Apellis said it wouldn't need the 24-mondecide approval.
On this news, APLS stocks declined 16% and the Company lost over $1 billion of its capitalization.
Taking the Company's previous representations and the unexpected decision into account, Investors have reasons to suspect that the Company's Leaders acted not in the best interest of Apellis' shareholders and misled them in material matters.
Alleged Offence
Misleading Statements,
Failure to Disclose,
Price manipulation,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Shareholder
Security Type
Stocks
Trade Direction
Long
Shock Event Date
03 November 2022